NCT00633347View on ClinicalTrials.gov

Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation

PHASE4CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Infertility
Interventions
DRUG

Antagonist GnRH Cetrotide

Cetrotide 0.25 mg. daily/ 7 days

DRUG

Agonist GnRH Acetate Triptoreline

Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose

Trial Locations (1)

46015

IVI Valencia, Valencia

All Listed Sponsors
lead

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

NCT00633347 - Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation | Biotech Hunter | Biotech Hunter